NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis $14.96 +0.03 (+0.17%) As of 12:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Amarin Stock (NASDAQ:AMRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amarin alerts:Sign Up Key Stats Today's Range$14.64▼$14.9850-Day Range$14.52▼$17.3352-Week Range$7.08▼$17.49Volume26,184 shsAverage Volume90,123 shsMarket Capitalization$309.27 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingReduce Company Overview Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies. The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events. Since its initial U.S. approval in 2012, Vascepa has received marketing authorizations in key markets including Canada, the European Union and Japan, often through strategic partnerships with regional pharmaceutical companies. Amarin manages its own commercial organization in the United States and leverages licensing agreements to support distribution and patient access abroad. In addition to its marketed portfolio, Amarin is conducting ongoing research to explore new indications for Vascepa and to expand its understanding of lipid-modifying therapies. Its clinical programs aim to investigate potential benefits in a range of cardiovascular and metabolic conditions. The company operates with a leadership team comprised of seasoned professionals in biopharmaceutical R&D, regulatory affairs and commercial strategy, supported by research facilities in the United States and Europe.AI Generated. May Contain Errors. Read More Amarin Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreAMRN MarketRank™: Amarin scored higher than 11% of companies evaluated by MarketBeat, and ranked 926th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingReduce Consensus RatingAmarin has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Downside RiskAmarin has a consensus price target of $12.00, representing about 19.6% downside from its current price of $14.93.Amount of Analyst CoverageAmarin has only been the subject of 2 research reports in the past 90 days.Read more about Amarin's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.15) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amarin's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.06% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Amarin has recently decreased by 0.05%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.06% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Amarin has recently decreased by 0.05%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment0.95 News SentimentAmarin has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Amarin this week, compared to 2 articles on an average week.Search Interest1 people have searched for AMRN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.96% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 22.25% of the stock of Amarin is held by institutions.Read more about Amarin's insider trading history. Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMRN Stock News HeadlinesIonis upgraded at BMO Capital Markets after data for lipid-lowering agentSeptember 3, 2025 | msn.comAmarin stock rises after ESC Congress data on VASCEPA mechanismSeptember 2, 2025 | investing.comTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …September 16 at 2:00 AM | Weiss Ratings (Ad)Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025August 31, 2025 | globenewswire.comNew REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces ...August 30, 2025 | finance.yahoo.comNew REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient SubgroupsAugust 30, 2025 | globenewswire.comWe're Not Worried About Amarin's (NASDAQ:AMRN) Cash BurnAugust 29, 2025 | finance.yahoo.comAmarin announces upcoming presentations at ESC Congress 2025August 25, 2025 | msn.comSee More Headlines AMRN Stock Analysis - Frequently Asked Questions How have AMRN shares performed this year? Amarin's stock was trading at $9.70 on January 1st, 2025. Since then, AMRN shares have increased by 53.9% and is now trading at $14.93. How were Amarin's earnings last quarter? Amarin Corporation PLC (NASDAQ:AMRN) posted its quarterly earnings data on Wednesday, July, 30th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.63. The biopharmaceutical company had revenue of $72.74 million for the quarter, compared to the consensus estimate of $45.45 million. Amarin had a negative net margin of 47.22% and a negative trailing twelve-month return on equity of 21.18%. Read the conference call transcript. When did Amarin's stock split? Amarin shares reverse split before market open on Friday, April 11th 2025.The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Does Amarin have any subsidiaries? Amarin subsidiaries include Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited. Who are Amarin's major shareholders? Top institutional shareholders of Amarin include Acadian Asset Management LLC (1.16%), SCP Investment LP (0.60%), Waterfront Wealth Inc. (0.46%) and BNP Paribas Financial Markets (0.37%). Insiders that own company stock include Aaron Berg, Steven B Ketchum and Patrick Holt. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings7/30/2025Today9/16/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMRN CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees360Year Founded1991Price Target and Rating Average Price Target for Amarin$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside-19.3%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($3.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.18 million Net Margins-47.22% Pretax Margin-44.91% Return on Equity-21.18% Return on Assets-15.00% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio2.34 Sales & Book Value Annual Sales$228.61 million Price / Sales1.34 Cash FlowN/A Price / Cash FlowN/A Book Value$23.62 per share Price / Book0.63Miscellaneous Outstanding Shares20,680,000Free Float20,278,000Market Cap$307.41 million OptionableOptionable Beta0.77 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:AMRN) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.